Clear cell renal cell carcinoma Trials in Atlanta, United States
Conditions / Clear cell renal cell carcinoma / Atlanta, United States
Clear cell renal cell carcinoma has been the subject of sustained clinical investigation across multiple research sites.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | COMPLETED | PHASE1/PHASE2 |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study | RECRUITING | PHASE1/PHASE2 |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00326898 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | COMPLETED | PHASE3 |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | COMPLETED | PHASE2 |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | TERMINATED | PHASE1/PHASE2 |
| NCT06661720 | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | RECRUITING | PHASE3 |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | TERMINATED | PHASE1/PHASE2 |